Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
Urology News
UROLOGY NEWS
Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Darolutamide Delays Pain Progression, Deterioration in Urinary Symptoms in High-Risk Nonmetastatic CRPC
Investigators from the phase 3 ARAMIS trial reported a significant delay in PSA progression in patients with nonmetastatic CRPC receiving darolutamide.
Prostate Cancer Detection Greater With Targeted Plus Systematic Biopsy
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
Advanced, Fatal Prostate Cancer Linked to High Visceral Fat
Greater visceral and thigh subcutaneous fat are associated with higher risks of advanced and fatal prostate cancer (PCa), according to a new prospective study. In addition, visceral fat is associated with a higher risk of these outcomes among men with a lower body mass index (BMI). Investigators found no association between any adiposity measure and…
Testicular Cancer Treatment Does Not Up Risk for Offspring Birth Defects
No increased risk seen at posttreatment in children of fathers with testicular germ-cell cancer
Benefit Seen from Frontline Pembrolizumab Plus Axitinib in Patients With Intermediate- or Poor-Risk Advanced RCC
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Combo Shows Promise in Advanced RCC With Brain Metastases
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Real-World Prostate Cancer Active Surveillance Less Than Ideal
In a study of prostate cancer patients from North Carolina, only 15% received monitoring as recommended by the NCCN.
Enzalutamide Ups Survival in Metastatic Hormone-Sensitive PCa
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
Want to read more?
Please login or register first to view this content.
Next post in Kidney Cancer
